In Re Brand Name Prescription Drugs Antitrust Litigation
Author | : |
Publisher | : |
Total Pages | : 120 |
Release | : 1997 |
Genre | : |
ISBN | : |
Download In Re Brand Name Prescription Drugs Antitrust Litigation Book in PDF, ePub and Kindle
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download In Re Brand Name Prescription Drugs Antitrust Litigation PDF full book. Access full book title In Re Brand Name Prescription Drugs Antitrust Litigation.
Author | : |
Publisher | : |
Total Pages | : 120 |
Release | : 1997 |
Genre | : |
ISBN | : |
Author | : Judith E. Usdam |
Publisher | : |
Total Pages | : |
Release | : 1996 |
Genre | : Pharmacy |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 40 |
Release | : 2008 |
Genre | : Antitrust law |
ISBN | : |
The plaintiffs in In re: Ciprofloxacin hydrochloride (Cipro) Antitrust Litigation (consumers and advocacy groups), sued the the brand name antibiotic's manufacturer Bayer, and prospective manufacturers of cheaper generic version, claiming that the exclusion agreement under which proposed manufacturers agreed to defer entry into market until expiration of patent held by Bayer, in return for payments to be received from Bayer, was in violation of antitrust laws. This amicus brief supports the plaintiffs, arguing in part that the case should have been decided in federal circuit court and that exclusion payments are generally anticompetitive.
Author | : |
Publisher | : |
Total Pages | : 42 |
Release | : 2005 |
Genre | : Antitrust law |
ISBN | : |
The plaintiffs in In re: Taxmoxifen Citrate Antitrust Litigation (who include pharmaceutical consumers, third party payors, and a health care advocacy group) filed a Petition for Writ of Certiorari asking the Supreme Court to review the Second Circuit's decision affirming the dismissal of this antitrust case. The plaintiffs alleged antitrust violations based on a $21 million payment from AstraZeneca (the tamoxifen NDA holder) to Barr Labs (the ANDA filer) in exchange for Barr's promise to withdraw its Paragraph IV certification and abandon its challenge of the tamoxifen patent.
Author | : |
Publisher | : DIANE Publishing |
Total Pages | : 186 |
Release | : |
Genre | : |
ISBN | : 9781422322987 |
Author | : |
Publisher | : |
Total Pages | : 44 |
Release | : 2005 |
Genre | : Antitrust law |
ISBN | : |
The case concerns a decision by a divided panel of the Appeals Court upholding the dismissal of an antitrust challenge to a patent litigation settlement between AstraZeneca, the manufacturer of tamoxifen citrate, the most widely prescribed drug for breast cancer treatment, and Barr Labs., a U.S. Food and Drug Administration applicant for a generic counterpart.
Author | : |
Publisher | : |
Total Pages | : 68 |
Release | : 1997 |
Genre | : |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 66 |
Release | : 1995 |
Genre | : |
ISBN | : |
Author | : |
Publisher | : U.S. Government Printing Office |
Total Pages | : 94 |
Release | : 1998 |
Genre | : Business & Economics |
ISBN | : |
Author | : |
Publisher | : DIANE Publishing |
Total Pages | : 129 |
Release | : 2002 |
Genre | : |
ISBN | : 1428951938 |